Gastric cancer
early detection test

About Us.

Ilico Genetics, a Spin Off of Pontificia Universidad Católica de Chile, is developing the first methylated DNA based molecular test specifically designed for the early detection of gastric cancer, even years before Esophagogastroduodenoscopy (EGD, gold standard).

With only a blood sample, and even without symptoms, it detects a tumor in the stomach or lesions that could evolve to gastric cancer. The results are dynamic and show the cumulative presence of tumors over time.

Our test:

Reduces treatment costs by ~ 90%, compared to advanced stages;
Timely results to prioritize patients at risk (“fast track”);
Screening potential due to its low cost and ease of implementation;
Monitoring capacity for the dynamic follow-up of premalignant lesions (i.e., gastric intestinal metaplasia or “GIM”).

Our Leadership Team.

We are a multinational, intergenerational, and multidisciplinary team with proven experience in cancer research, laboratory operations, and business management. Our aspiration is to impact the lives of patients and their families by developing innovative genomic solutions.